Business Model Breakdown
How agilon health inc Makes Money
AGL
Market Cap
$449M
Annual Revenue
$5.9B
Profit Margin
-6.6%
The Short Version
agilon health partners with local primary care physicians (PCPs) to help them transition from a traditional fee-for-service payment model to a value-based care model, primarily for their senior patients (Medicare Advantage). Instead of billing for each service, agilon health's model involves receiving a fixed payment per patient (capitation) from health plans. In return, agilon provides PCPs with technology, data analytics, and operational support to better manage patient care, improve health outcomes, and reduce overall healthcare costs. The company's revenue is tied to the capitated payments and its ability to manage patient costs efficiently, sharing the financial risk and rewards with the partnered physicians.
Where the Revenue Comes From
Capitated payments from health plans for managing patient care (~100% of revenue)
Who buys: Primary care physician practices (its direct customers) and Medicare Advantage health plans (which provide the capitated payments), ultimately serving senior patients.
Why It Works (Competitive Advantages)
- ✔Value-based care model aligned with industry shift towards quality and cost efficiency
- ✔Strong relationships and network with primary care physicians for Medicare Advantage
- ✔Scalable technology platform for data analysis and care coordination
Economic Moat: Narrow (Switching Costs (for physician practices integrated into their platform), Intangible Assets/IP (data analytics and care protocols), Efficient Scale (as network expands, efficiency and data insights improve))
What Our Analysis Says
DVR Score as of May 5, 2026
agilon health operates in the high-growth value-based care segment, partnering with physicians for Medicare Advantage patients, which offers significant TAM. However, the company faces severe profitability issues with negative net margins and ROE in Q4 2025, alongside only 3.1% YoY revenue growth. The recent 1-for-25 reverse stock split and new CEO appointment indicate a company in significant distress and undergoing a pivot/turnaround, not one currently exhibiting strong financial health or momentum. While the business model is scalable and strategic, the path to 10x growth within 3-5 years is highly uncertain due to current operational losses and a weak financial position. The extremely low P/S ratio (approx. 0.077x based on annualized Q4 2025 revenue) suggests deep market skepticism. Achieving a 10x return would require a substantial shift to profitability and a significant re-rating of its valuation multiple, which is a high-risk, high-reward proposition.